

<110> APHTON CORPORATION

<120> Prevention and Treatment of Hypergastrinemia

<130> 1102865-0035

<140> US

<141> 1999-05-14

<150> US 60/085,714

<151> 1999-05-15

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 9

<212> PRT

<213> human or synthetic

<220>

<221> MOD_RES

<222> (1)

<223> pyroglutamic acid

<400> 1

Glu Gly Pro Trp Leu Glu Glu Glu Glu

1

5

<210> 2

<211> 12

<212> PRT

<213> human or synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> pyroglutamic acid

<400> 2

Glu Leu Gly Pro Gln Gly Arg Pro Pro Pro Pro Cys

1

5

10

<210> 3
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic
peptide

<400> 3
Ser Ser Pro Pro Pro Pro Cys
1 5

<210> 4
<211> 7
<212> PRT
<213> human or synthetic peptide

<220>
<221> MOD_RES
<222> (7)
<223> AMIDATION

<400> 4
Glu Ala Tyr Gly Trp Met Asp
1 5